134 related articles for article (PubMed ID: 2589233)
1. Effective control of CMF-related emesis with high-dose dexamethasone: results of a double-blind crossover trial with metoclopramide and placebo.
Pollera CF; Nardi M; Marolla P; Pinnaró P; Terzoli E; Giannarelli D
Am J Clin Oncol; 1989 Dec; 12(6):524-9. PubMed ID: 2589233
[TBL] [Abstract][Full Text] [Related]
2. High-dose metoclopramide and dexamethasone as an antiemetic in outpatients receiving chemotherapy for breast cancer. Second study.
Gez E; Warner-Efraty E; Ben-Yosef R; Ben-Baruch N; Yitzhaki N; Uziely B; Brufman G; Biran S
Oncology; 1987; 44(4):237-9. PubMed ID: 3614813
[TBL] [Abstract][Full Text] [Related]
3. High-dose metoclopramide and dexamethasone as an antiemetic in chemotherapy of breast cancer.
Gez E; Goodman S; Isacson R; Gerra C; Sulkes A
Oncology; 1986; 43(3):173-5. PubMed ID: 3754627
[TBL] [Abstract][Full Text] [Related]
4. Methylprednisolone versus metoclopramide as antiemetic treatment in patients receiving adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) chemotherapy: a randomized crossover blind study.
Gez E; Sulkes A; Ochayon L; Gera C; Nathan S; Cass Y; Rubello E; Biran S
J Chemother; 1989 Dec; 1(6):365-8. PubMed ID: 2693621
[TBL] [Abstract][Full Text] [Related]
5. High-dose intravenous metoclopramide versus combination high-dose metoclopramide and intravenous dexamethasone in preventing cisplatin-induced nausea and emesis: a single-blind crossover comparison of antiemetic efficacy.
Strum SB; McDermed JE; Liponi DF
J Clin Oncol; 1985 Feb; 3(2):245-51. PubMed ID: 4038511
[TBL] [Abstract][Full Text] [Related]
6. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.
Levitt M; Warr D; Yelle L; Rayner HL; Lofters WS; Perrault DJ; Wilson KS; Latreille J; Potvin M; Warner E
N Engl J Med; 1993 Apr; 328(15):1081-4. PubMed ID: 8455665
[TBL] [Abstract][Full Text] [Related]
7. Randomized open cross-over trial between metoclopramide (MCP) and dexamethazone (DXM) for the prevention of cisplatin-induced nausea and vomiting.
Cognetti F; Pinnarò P; Carlini P; Conti EM; Cortese M; Pollera CF
Eur J Cancer Clin Oncol; 1984 Feb; 20(2):183-7. PubMed ID: 6368241
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial comparing alizapride alone or with dexamethasone vs a metoclopramide-dexamethasone combination for emesis induced by moderate-dose cisplatin.
Pollera CF; Nardi M; Marolla P; Carlini P
Cancer Chemother Pharmacol; 1987; 19(4):335-8. PubMed ID: 3297376
[TBL] [Abstract][Full Text] [Related]
9. An audit of antiemetic use with CMF chemotherapy.
Brown RS; Brown TK; Hoare D; Gaze MN
Clin Oncol (R Coll Radiol); 1998; 10(5):313-7. PubMed ID: 9848332
[TBL] [Abstract][Full Text] [Related]
10. The antiemetic efficacy of methylprednisolone compared with metoclopramide in outpatients receiving adjuvant CMF chemotherapy for breast cancer: a randomized trial.
Campora E; Chiara S; Bruzzi P; Scarsi P; Rosso R
Tumori; 1985 Oct; 71(5):459-62. PubMed ID: 3904102
[TBL] [Abstract][Full Text] [Related]
11. Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study.
Buser KS; Joss RA; Piquet D; Aapro MS; Cavalli F; Haefliger JM; Jungi WF; Bauer J; Obrist R; Brunner KW
Ann Oncol; 1993 Jun; 4(6):475-9. PubMed ID: 8353089
[TBL] [Abstract][Full Text] [Related]
12. Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide methotrexate 5-fluorouracil: a double-blind randomized study.
Roila F; Basurto C; Minotti V; Ballatori E; Tonato M; Del Favero A
Oncology; 1988; 45(5):346-9. PubMed ID: 3412741
[TBL] [Abstract][Full Text] [Related]
13. Alizapride alone or alizapride-dexamethasone compared with metoclopramide-dexamethasone in patients at high risk of acute emesis after cisplatin. A randomized cross-over study.
Pollera CF; Nardi M; Marolla P; Calabresi F
Acta Oncol; 1991; 30(6):725-9. PubMed ID: 1958393
[TBL] [Abstract][Full Text] [Related]
14. Antiemetic efficacy of nabilone and dexamethasone: a randomized study of patients with lung cancer receiving chemotherapy.
Niiranen A; Mattson K
Am J Clin Oncol; 1987 Aug; 10(4):325-9. PubMed ID: 3039831
[TBL] [Abstract][Full Text] [Related]
15. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854
[TBL] [Abstract][Full Text] [Related]
16. Comparison of metoclopramide and metoclopramide plus dexamethasone for complete protection from cisplatinum-induced emesis.
Grunberg SM; Akerley WL; Krailo MD; Johnson KB; Baker CR; Cariffe PA
Cancer Invest; 1986; 4(5):379-85. PubMed ID: 3801953
[TBL] [Abstract][Full Text] [Related]
17. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
Sorbe BG
Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
[TBL] [Abstract][Full Text] [Related]
18. Chlorpromazine and dexamethasone versus high-dose metoclopramide and dexamethasone in patients receiving cancer chemotherapy, particularly cis-platinum: a prospective randomized crossover study.
Gez E; Ben-Yosef R; Catane R; Brufman G; Biran S
Oncology; 1989; 46(3):150-4. PubMed ID: 2654792
[TBL] [Abstract][Full Text] [Related]
19. [Use of dexamethasone as an antiemetic in patients with breast cancer treated with the CMF regimen].
Domaradzka-Woźniak A; Wojtacki J; Dziewulska-Bokiniec A
Przegl Lek; 1994; 51(5):203-5. PubMed ID: 7938648
[TBL] [Abstract][Full Text] [Related]
20. Methylprednisolone as antiemetic treatment in breast-cancer patients receiving cyclophosphamide, methotrexate, and 5-fluorouracil: a prospective, crossover, randomized blind study comparing two different dose schedules.
Gez E; Strauss N; Vitzhaki N; Cass Y; Edelmann DZ
Cancer Chemother Pharmacol; 1992; 30(3):229-32. PubMed ID: 1628373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
